NXTC · Nextcure, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $22.38M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $44.92M | $41.49M | $47.93M | $54.20M | $50.19M | $46.55M |
| SG&A | $12.69M | $15.72M | $19.71M | $21.71M | $20.57M | $17.05M |
| Total Operating Expenses | $57.62M | $59.75M | $67.64M | $75.91M | $70.77M | $63.60M |
| D&A | $2.20M | $2.90M | $3.70M | $4.10M | $4.30M | $3.41M |
| Operating Income | ($57.62M) | ($59.75M) | ($67.64M) | ($75.91M) | ($70.77M) | ($41.23M) |
| Interest Expense | - | - | - | - | - | $183.0K |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | ($55.84M) | ($55.65M) | ($62.72M) | ($74.73M) | ($69.39M) | ($36.60M) |
| EPS - Basic | ($19.65) | ($1.99) | ($2.25) | ($2.69) | ($1.33) | - |
| EPS - Diluted | ($19.65) | ($1.99) | ($2.25) | ($2.69) | ($1.33) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.98M | $27.73M | $13.08M | $26.63M | $12.34M | $32.77M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.01M | $5.35M | $2.33M | $4.27M | $1.94M | $3.90M |
| Current Assets | $43.75M | $71.81M | $112.72M | $163.98M | $227.82M | $287.98M |
| Total Assets | $50.18M | $80.86M | $128.04M | $184.16M | $242.39M | $306.64M |
| Current Liabilities | $10.57M | $9.57M | $6.88M | $9.13M | $6.61M | $10.32M |
| Long-term Debt | - | - | - | $0 | $0 | $1.81M |
| Total Liabilities | $15.24M | $15.39M | $13.62M | $16.63M | $9.00M | $12.92M |
| Stockholders' Equity | $34.94M | $65.47M | $114.42M | $167.53M | $233.39M | $293.72M |
| Retained Earnings | ($435.98M) | ($380.14M) | ($324.48M) | ($261.76M) | ($187.03M) | ($117.64M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($49.61M) | ($40.80M) | ($52.97M) | ($53.89M) | ($57.24M) | ($44.95M) |
| Investing Cash Flow | $25.56M | $55.31M | $39.27M | $67.98M | $36.60M | $43.52M |
| Financing Cash Flow | $22.31M | $144.0K | $154.0K | $200.0K | ($3.27M) | ($1.42M) |
| CapEx | - | $474.0K | $820.0K | $2.12M | $2.36M | $7.13M |
| Free Cash Flow | - | ($41.28M) | ($53.79M) | ($56.00M) | ($59.60M) | ($52.09M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | -184.2% |
| EBITDA margin | - | - | - | - | - | -169.0% |
| Net margin | - | - | - | - | - | -163.6% |
| Free cash flow margin | - | - | - | - | - | -232.8% |
| FCF / Net income | - | 0.74 | 0.86 | 0.75 | 0.86 | 1.42 |
| R&D / Revenue | - | - | - | - | - | 208.0% |
| SG&A / Revenue | - | - | - | - | - | 76.2% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -111.3% | -68.8% | -49.0% | -40.6% | -28.6% | -11.9% |
| Return on equity | -159.8% | -85.0% | -54.8% | -44.6% | -29.7% | -12.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.14 | 7.50 | 16.38 | 17.97 | 34.48 | 27.89 |
| Quick ratio | 4.14 | 7.50 | 16.38 | 17.97 | 34.48 | 27.89 |
| Cash ratio | 2.46 | 2.90 | 1.90 | 2.92 | 1.87 | 3.17 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.00 | 0.00 | 0.01 |
| Debt / Assets | - | - | - | 0.00 | 0.00 | 0.01 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -225.3x |
| Equity multiplier | 1.44 | 1.24 | 1.12 | 1.10 | 1.04 | 1.04 |
| Liabilities / Assets | 0.30 | 0.19 | 0.11 | 0.09 | 0.04 | 0.04 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | 0.07 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | 252.6% |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 3.6% | 11.7% | 10.9% | -7.3% | -71.7% | -77.7% |
| Net income growth (YoY) | -0.3% | 11.3% | 16.1% | -7.7% | -89.6% | -60.5% |
| EPS growth (YoY) | -887.4% | 11.6% | 16.4% | -102.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 23.3% | 3.9% | 6.0% | -14.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -46.6% | -42.8% | -31.7% | -28.2% | -20.5% | -8.6% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NextCure against the 5 most active filers in the same SIC group.